3 Under-the-radar Stocks To Buy And Hold For A Decade
1. Madrigal Pharmaceuticals
Madrigal Pharmaceuticals made history in 2024 when it earned approval for Rezdiffra, the first medicine for metabolic dysfunction-associated steatohepatitis (MASH). There was a dire need for a treatment for MASH when Madrigal first entered the field: Millions of patients in the U.S. alone suffer from the disease. Sure enough, Madrigal Pharmaceuticals has made significant headway in this market. As of March 31, more than 42,250 patients were being treated with Rezdiffra. Madrigal Pharmaceuticals’ first-quarter revenue increased by 127% year over year to $311.3 million, driven by Rezdiffra, the company’s only approved medicine.
Expand
NASDAQ: MDGL
Madrigal Pharmaceuticals
Today’s Change
(3.95%) $18.99
Current Price
$499.76
Key Data Points
Market Cap
$12B
Day’s Range
$474.52 – $500.71
52wk Range
$275.00 – $615.00
Volume
1.5
Avg Vol
312K
Gross Margin
92.94%
Yet, the biotech company still has a large addressable market. Madrigal Pharmaceuticals is targeting about 315,000 MASH patients who are being seen by specialists. It still has a long way to go before capturing even 50% of this addressable opportunity. Further, Madrigal Pharmaceuticals has a pipeline of additional assets that will address the needs of even more MASH patients.
The company could make significant progress in this niche over the next decade while delivering solid top-line growth. There are some risks, including increased competition. Novo Nordisk also earned approval for a medicine for MASH last year. There will be more brand-new market entrants in the future. Further, Madrigal Pharmaceuticals could encounter clinical or regulatory setbacks that might sink the stock. But even with these caveats, the company’s leading product, strong pipeline, and first-mover advantage in this niche could allow it to deliver excellent returns over the next 10 years.
2. Axsome Therapeutics
Axsome Therapeutics has several products in its portfolio that are driving solid top-line growth. The list includes Auvelity, a depression medicine that is its main growth pillar. In the first quarter, Axsome Therapeutics’ top line increased by 57% year over year to $191.2 million. Auvelity’s sales came in at $153.2 million, 59% higher than the year-ago period. Here’s the great news: Auvelity just earned a label expansion for the treatment of Alzheimer’s disease agitation.
This new indication should meaningfully move the needle for Axsome Therapeutics. Here’s why. Although AD agitation affects more than five million people in the U.S., there is a dire need for new treatment options, considering there weren’t many that were FDA-approved. Axsome Therapeutics’ Auvelity will help fill that need. The drugmaker now projects peak sales of $8 billion for Auvelity.
Expand
NASDAQ: AXSM
Axsome Therapeutics
Today’s Change
(-0.69%) $-1.77
Current Price
$253.40
Key Data Points
Market Cap
$13B
Day’s Range
$251.14 – $255.09
52wk Range
$96.09 – $257.93
Volume
628.4K
Avg Vol
717K
Gross Margin
91.30%
Meanwhile, Axsome Therapeutics’s trailing-12-month revenue is only $708.24 million. And beyond Auvelity, the company should rely on other growth drivers as well. Axsome Therapeutics’ migraine treatment, Symbravo, was approved early last year and is slowly ramping up sales.
The biotech should also launch new products. Axsome Therapeutics requested approval for AXS-12, an investigational medicine for cataplexy associated with narcolepsy. Further, the drugmaker has several exciting phase 3 pipeline programs that could lead to new approvals or label expansions. Axsome Therapeutics has outpaced broader equities over the past five years, and the company could do the same through 2036 if it continues to make solid clinical progress while delivering excellent financial results.
3. Kailera Therapeutics
Kailera Therapeutics is a biotech company that recently went public. The drugmaker specializes in developing weight loss medicines. UnMadrigal Pharmaceuticals and Axsome Therapeutics, Kailera Therapeutics doesn’t have a single marketed drug. That makes it riskier. However, investing in this company may be a great way to capitalize on the fast-growing anti-obesity market. This therapeutic area is projected to grow significantly over the next five to 10 years.
And although pharmaceutical giants such as Novo Nordisk and Eli Lilly are currently the leaders in this niche, there may be plenty of room for smaller players Kailera Therapeutics to carve out a niche. The biotech’s pipeline is promising, too, with several exciting candidates that are making progress. Kailera Therapeutics’ leading candidate, ribupatide injection, is currently being tested in phase 3 studies.
Expand
NASDAQ: KLRA
Kailera Therapeutics
Today’s Change
(4.13%) $0.78
Current Price
$19.67
Key Data Points
Market Cap
$2.5B
Day’s Range
$19.10 – $20.02
52wk Range
$16.00 – $28.23
Volume
404K
Avg Vol
781.5K
Importantly, ribupatide mimics the action of two separate gut hormones: GLP-1 and GIP. Many scientists believe that this approach may offer greater efficacy than traditional GLP-1 medicines Wegovy. Meanwhile, Kailera Therapeutics is developing an oral version of ribupatide, for which it is planning to start phase 3 studies next year.
And the company has another asset in phase 1 clinical trials, KAI-4729, that mimics the action of three separate gut hormones: GLP-1, GIP, and glucagon. Again, Kailera Therapeutics is on the risky side. However, if it can make waves in the large and growing weight-loss market over the next five years, it could deliver excellent returns. Those comfortable with volatility should consider initiating small positions in this stock.
Read Next
•By Keith Speights
Biotech vs. Pharma: What’s the Difference?
CVS Health’s Comeback Is Just Getting Started — and Its Valuation Still Looks Shockingly Cheap
Tilray’s Stock Is Down 45% This Year, and Here’s Why It Could Still Go Lower
•By Thomas Niel
1 Top Wall Street Analyst Thinks CVS Health Could Jump Another 13%. Should You Load Up on the Stock?
•By Pamela Kock
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
•By Trevor Jennewine
Prediction: This Will Be Micron’s Stock Price by Late 2027 (Hint: It Implies Big Gains)
About the Author
Prosper Junior Bakiny is a contributing Motley Fool healthcare analyst covering biotechnology, pharmaceuticals, and healthcare stocks. Before The Motley Fool, Prosper wrote about investing topics ranging from stock market news to private equity for various companies. He holds a master’s degree in corporate finance from the University of Maryland Global Campus.
Stocks Mentioned
Madrigal Pharmaceuticals
NASDAQ: MDGL
$499.76
(+3.95%)+$18.99
Motley Fool Stock Advisor’s Latest Pick
—% Avg Return
Eli Lilly
NYSE: LLY
$1,130.24
(-0.24%)-$2.76
Novo Nordisk
NYSE: NVO
$43.86
(-0.06%)-$0.03
Axsome Therapeutics
NASDAQ: AXSM
$253.40
(-0.69%)-$1.77
Kailera Therapeutics
NASDAQ: KLRA
$19.67
(+4.13%)+$0.78
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Sumber Artikel:
Fool.com